PATENT COOPERATION TREATY

From th	-	NAL SEARCHI	NG AUTHOR	ITY		"ANO.
To:						PCT PCT
						RITTEN OPINION OF THE IONAL SEARCHING AUTHORITY
						(PCT Rule 43bis.1)
					Date of mailing (day/month/year)	See form PCT/ISA/210
	ant's or a	gent's file referen	ice		FOR FURTHER A	ACTION See paragraph 2 below
Internat	ional ap	plication No.		International filing date	(day/month/year)	Priority date (day/month/year)
PCI	'/EP	2005/002	057	26.02.2005		28.02.2004
Applica	ını			, C08B30/20,		8, C08B35/00,A61K47/48
2.	FURT If a continuation of this Internation of the PCT/I	Box No. II Box No. III Box No. IVI Box No. VI Box No. VII Box No. VIII FHER ACTION Idemand for international Prelimination on to be the teternational Searce opinion is, as proncessor opens of the present the control of the control opens of the control opinion is, as proncessor opinion is, as pron	Basis of the Priority Non-establis Lack of unit Reasoned strapplicability Certain docu Certain defe Certain obse national prelin ry Examining a IPEA and the hing Authority evided above, where approp-	shment of opinion with re- y of invention atement under Rule 43bis citations and explanation aments cited cts in the international approximations on the internation ininary examination is m Authority ("IPEA") excep chosen IPEA has notified will not be so considered considered to be a writte oriate, with amendments, of 22 months from the pr	gard to novelty, invention of the IPEA before the expiration	be considered to be a written opinion of the ly where the applicant chooses an Authority other au under Rule 66.1 bis(b) that written opinions of the applicant is invited to submit to the IPEA a of 3 months from the date of mailing of Form
3.	For fu	rther details, see	notes to Form I	PCT/ISA/220.		
Name a	nd maili	ng address of the	ISA/EP		Authorized officer	
Facsimi	le No.				Telephone No.	

International application No.

PCT/EP2005/002057

Box	No. I	Basis of this opinion
1.	With filed.	regard to the language, this opinion has been established on the basis of the international application in the language in which it was unless otherwise indicated under this item.
		This opinion has been established on the basis of a translation from the original language into the following language . which is the language of a translation furnished for the purposes of international search (under
		Rule 12.3 and 23.1(b)).
2.	With inver	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed attion, this opinion has been established on the basis of:
	a.	type of material
		a sequence listing
		table(s) related to the sequence listing
	b.	format of material
		in written format
		in computer readable form
	c.	time of filing/furnishing
		contained in the international application as filed.
		filed together with the international application in computer readable form.
		furnished subsequently to this Authority for the purposes of search.
3.		In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Addi	tional comments:

International application No.
PCT/EP2005/002057

Box	x No. II Priority
1.	The following document has not yet been furnished:
	copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).
	translation of the earlier application whose priority has been claimed (Rule +3bis.1 and 66.7(b)).
	Consequently it has not been possible to consider the validity of the priority claim. This opinion has nevertheless been established on the assumption that the relevant date in the claimed priority date.
2.	This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43bis.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.
3.	Additional observations, if necessary:
	The validity of the priority claim has not been considered because
	the International Searching Authority does not have in its
	possession a copy of the earlier application whose priority has been
	claimed or, where required, a translation of that earlier
	application. This opinion has nevertheless been established on the
	assumption that the relevant date (Rules 43bis1 and 64.1) is the
	claimed priority date.
İ	
	,

International application No.
PCT/EP2005/002057

Box	i No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applical citations and explanations supporting such statement	oility;
1.	Statemen	ent	
	Nove	elty (N) Claims 1-8 Claims	
	Inven	ntive step (IS) Claims 1-8	
	Indus	cstrial applicability (IA) Claims 1-8 Claims	
2.	Citations	s and explanations:	
	1.	Documents	
	1.1	This opinion cites the following search report citations (D); the same numbering will be used throughout the procedure:	
	1.2	D1: US5886168 D2: US20040014961 D3: GB2342656	
	2.	Novelty (PCT Article 33(3))	
-	2.1	The present application meets the requirements of PCT Article 32(2) because the subject matter of claims 1-8 is novel under PCT Rule 64(1) to (3).	
	3.	<pre>Inventive step (PCT Article 33(3))</pre>	
	3.1	The present application does not meet the requirements of PCT Article 33(3) because the subject matter of claims 1-8 is not inventive under PCT Rule 65(1) to (2).	
	3.2	Claim 1 of the application describes a process for preparing hyperbranched amylopectin having a molecular weight of \geq 2000 daltons and \leq 30 000 daltons and a degree of branching of \geq 10% and \leq 20%. The process consists of two hydrolysis steps 1) by means of α -amylase or acid hydrolysis, the molecula weight of the amylopectin is degraded to \leq 60 000 daltons,	:

International application No.
PCT/EP2005/002057

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

- by means of β -amylase, the molecular weight of the degradation product from the first step is degraded further, to the desired 2000-30 000 daltons.
- 3.3 Document **D1**, which is considered to be the closest prior art, discloses (abstract, claim 1, examples) a process for preparing branched amylopectin having a molecular weight of 20 000-50 000 daltons utilizing α -amylase.
- 3.4 The process of claim 1 of the application differs from D1 in that a second β -amylase step is performed in order to bring the amylopectins to a molecular weight of 2000-30 000 daltons and a degree of branching of 10-20%.
- 3.5 However, this difference cannot be considered to be inventive.
- 3.6 **D2** (paragraphs 121, 122) discloses a process for preparing branched amylopectin having a degree of branching of 10-30% by performing a second hydrolysis step with, for example, β -amylase in order to increase the degree of branching and to degrade the molecular weight.
- 3.7 A person skilled in the art with knowledge of **D1** and with the problem of preparing an amylopectin with molecular weight of 2000-30 000 and a degree of branching of 10-20% would utilize the disclosure of **D2** in order to achieve the further degradation and the desired degree of branching of the amylopectin of the **D1** process. A person skilled in the art would, without thereby needing to be inventive, arrive at the optimal reaction conditions.
- 3.8 It also becomes clear from D3 (abstract) that α -amylase and acid hydrolysis can be considered as alternative processes to arrive at a degraded amylopectin.
- 3.9 Claim 1 therefore cannot be considered to be inventive.
- 3.10 Dependent claims 2-8 do not contain any features which, in

International application No.
PCT/EP2005/002057

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

combination with the features of any claim to which they refer, meet the PCT requirements for inventive step. Claims 2-8 are therefore considered not to be inventive over the cited prior art and/or the common general knowledge of a person skilled in the art.

4. Further remarks

- 4.1 At page 4 line 17 the molecular weight is reported as \leq 29 000. However, claim 1 reports the molecular weight as \leq 30 000.
- 4.2 The cited document DE10254754.9 (page 7 line 13) cannot be found.
- 4.3 Pursuant to PCT Rule 5.1(a)(ii), the description should have cited documents D1-D3 and briefly outlined the relevant prior art contained therein.

International application No.

PCT/EP2005/002057

	No. VI Certain documents cited			
1.	Certain published documents (Rule 43bis.1 and 70	0.10)		
	Application No. Patent No.	Publication date (day/month/year)	Filing date (day/month/year)	Priority date (valid claim) (day/month/year)
	WO2004050710	17.06.2004	03.12.2003	04.12.2002
		·		
2	Non-written disclosures (Rule 43bis.1 and 70.9)			
l .	,			
	Kind of non-written disclosure	Date of non-written di (day/month/yea	sclosure referring	e of written disclosure to non-written disclosure (day/month/year)
			sclosure referring	to non-written disclosure
			sclosure referring	to non-written disclosure
			sclosure referring	to non-written disclosure
			sclosure referring	to non-written disclosure
			sclosure referring	to non-written disclosure
			sclosure referring	to non-written disclosure
			sclosure referring	to non-written disclosure
			sclosure referring	to non-written disclosure
			sclosure referring	to non-written disclosure
			sclosure referring	to non-written disclosure
			sclosure referring	to non-written disclosure
			sclosure referring	to non-written disclosure
			sclosure referring	to non-written disclosure
See			sclosure referring	to non-written disclosure